ICAD INC (ICAD)

US44934S2068 - Common Stock

1.83  +0.06 (+3.39%)

After market: 1.83 0 (0%)

Fundamental Rating

3

ICAD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. No worries on liquidiy or solvency for ICAD as it has an excellent financial health rating, but there are worries on the profitability. ICAD does not seem to be growing, but still is valued expensively.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

ICAD had negative earnings in the past year.
In the past year ICAD has reported a negative cash flow from operations.
In the past 5 years ICAD always reported negative net income.
ICAD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -7.30%, ICAD is doing good in the industry, outperforming 72.22% of the companies in the same industry.
Looking at the Return On Equity, with a value of -9.22%, ICAD is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
ROA -7.3%
ROE -9.22%
ROIC N/A
ROA(3y)-18.74%
ROA(5y)-24.07%
ROE(3y)-25.94%
ROE(5y)-80.55%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ICAD has a Gross Margin of 85.99%. This is amongst the best in the industry. ICAD outperforms 88.89% of its industry peers.
ICAD's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ICAD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.9%
GM growth 5Y2.4%

More info and screens

7

2. Health

2.1 Basic Checks

ICAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
ICAD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ICAD has more shares outstanding
There is no outstanding debt for ICAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ICAD has an Altman-Z score of -6.04. This is a bad value and indicates that ICAD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.04, ICAD is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
ICAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.04
ROIC/WACCN/A
WACC11.02%

2.3 Liquidity

A Current Ratio of 4.02 indicates that ICAD has no problem at all paying its short term obligations.
ICAD has a Current ratio of 4.02. This is amongst the best in the industry. ICAD outperforms 83.33% of its industry peers.
A Quick Ratio of 3.91 indicates that ICAD has no problem at all paying its short term obligations.
The Quick ratio of ICAD (3.91) is better than 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 3.91

More info and screens

2

3. Growth

3.1 Past

ICAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.67%, which is quite impressive.
ICAD shows a decrease in Revenue. In the last year, the revenue decreased by -0.68%.
Measured over the past years, ICAD shows a decrease in Revenue. The Revenue has been decreasing by -7.53% on average per year.
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)-0.68%
Revenue growth 3Y-16.46%
Revenue growth 5Y-7.53%
Sales Q2Q%3.54%

3.2 Future

ICAD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.53% yearly.
ICAD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.13% yearly.
EPS Next Y-11.27%
EPS Next 2Y-6.94%
EPS Next 3Y4.53%
EPS Next 5YN/A
Revenue Next Year-6.55%
Revenue Next 2Y-1.53%
Revenue Next 3Y4.13%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ICAD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICAD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.94%
EPS Next 3Y4.53%

More info and screens

0

5. Dividend

5.1 Amount

ICAD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICAD INC

NASDAQ:ICAD (12/20/2024, 8:17:46 PM)

After market: 1.83 0 (0%)

1.83

+0.06 (+3.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners25.59%
Inst Owner Change-8.35%
Ins Owners5.63%
Ins Owner Change0%
Market Cap48.57M
Analysts84
Price Target4.46 (143.72%)
Short Float %1.14%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.71%
Min EPS beat(2)11.77%
Max EPS beat(2)17.64%
EPS beat(4)4
Avg EPS beat(4)60.98%
Min EPS beat(4)11.77%
Max EPS beat(4)191.92%
EPS beat(8)7
Avg EPS beat(8)39.65%
EPS beat(12)7
Avg EPS beat(12)20.28%
EPS beat(16)9
Avg EPS beat(16)15.05%
Revenue beat(2)1
Avg Revenue beat(2)1.47%
Min Revenue beat(2)-8.54%
Max Revenue beat(2)11.48%
Revenue beat(4)3
Avg Revenue beat(4)5.07%
Min Revenue beat(4)-8.54%
Max Revenue beat(4)11.48%
Revenue beat(8)3
Avg Revenue beat(8)-3.87%
Revenue beat(12)3
Avg Revenue beat(12)-12.07%
Revenue beat(16)5
Avg Revenue beat(16)-8.35%
PT rev (1m)-9.48%
PT rev (3m)-9.48%
EPS NQ rev (1m)2.5%
EPS NQ rev (3m)-39.28%
EPS NY rev (1m)11.11%
EPS NY rev (3m)11.11%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)-9.11%
Revenue NY rev (1m)-2.65%
Revenue NY rev (3m)-2.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.56
P/FCF N/A
P/OCF N/A
P/B 1.65
P/tB 2.32
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.71
BVpS1.11
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.3%
ROE -9.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.99%
FCFM N/A
ROA(3y)-18.74%
ROA(5y)-24.07%
ROE(3y)-25.94%
ROE(5y)-80.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.9%
GM growth 5Y2.4%
F-Score5
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 114.87%
Cap/Sales 3.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 3.91
Altman-Z -6.04
F-Score5
WACC11.02%
ROIC/WACCN/A
Cap/Depr(3y)144.24%
Cap/Depr(5y)111.87%
Cap/Sales(3y)2.99%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-11.27%
EPS Next 2Y-6.94%
EPS Next 3Y4.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.68%
Revenue growth 3Y-16.46%
Revenue growth 5Y-7.53%
Sales Q2Q%3.54%
Revenue Next Year-6.55%
Revenue Next 2Y-1.53%
Revenue Next 3Y4.13%
Revenue Next 5YN/A
EBIT growth 1Y42.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.09%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y60.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.71%
OCF growth 3YN/A
OCF growth 5YN/A